Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bevacizumab biosimilar - Innovent Biologics

Next Previous
Drug Profile

Bevacizumab biosimilar - Innovent Biologics

Alternative Names: Avastin biosimilar- Innovent Biologics; Bevagen; BYVASDA; CHS-305; IBI 305

Latest Information Update: 07 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovent Biologics
  • Developer Chinese Academy of Medical Sciences; Innovent Biologics; PT Etana Biotechnologies Indonesia
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cervical cancer; Colorectal cancer; Glioblastoma; Liver cancer; Non-small cell lung cancer; Ovarian cancer
  • Registered Triple negative breast cancer

Most Recent Events

  • 30 Jun 2023 Innovent Biologics completes the phase III ORIENT-31 trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in China (IV) (NCT03802240)
  • 08 Sep 2022 Efficacy data from a phase III ORIENT-31 trial in Non-small cell lung cancer presented at the European Society for Medical Oncology Congress (ESMO-2022)
  • 13 Jun 2022 Launched for Cervical cancer (Late-stage disease) in China (IV) before June 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top